Digicann Ventures Inc. (AGFAF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 2.27: the stock has moved about 127% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerDigicann Ventures Inc. (AGFAF) trades at $0.0036. Digicann Ventures Inc., formerly Agra Ventures Ltd., operates within the cannabis industry, headquartered in Vancouver, Canada. Sector: Healthcare.
Price as of · Last analyzed: Jun 15, 2026Analyst Coverage for AGFAF: AGFAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Digicann Ventures Inc. (AGFAF) Healthcare & Pipeline Overview
Digicann Ventures Inc. is a Vancouver-based company operating in the evolving cannabis industry, categorized under specialty and generic drug manufacturing. Incorporated in 2004, the firm rebranded in August 2023, positioning itself within the healthcare sector amidst a dynamic regulatory and market landscape.
What Is the Investment Thesis for AGFAF?
Digicann Ventures Inc. operates within the rapidly evolving cannabis industry, categorized as a specialty and generic drug manufacturer. The company's rebranding from Agra Ventures Ltd. to Digicann Ventures Inc. in August 2023 suggests a strategic repositioning to capitalize on emerging trends or specific niches within the sector. Financially, the company exhibits a significant negative profit margin of -5863.2%, indicating substantial unprofitability, yet maintains a positive gross margin of 45.1%, suggesting some efficiency in its core production or service delivery before operating expenses. Its market capitalization is currently $0.00B, reflecting a micro-cap status. The high beta of 2.27 indicates substantial volatility relative to the broader market, characteristic of early-stage or speculative ventures in nascent industries like cannabis. The company's OTC listing and unknown disclosure status present additional considerations regarding transparency and liquidity. Future value drivers could stem from regulatory advancements in the cannabis sector, successful product development in specialty cannabis therapeutics, or strategic partnerships that improve operational scale and market access. However, the ongoing unprofitability and inherent risks of the cannabis market, coupled with the challenges of an OTC listing, require careful evaluation.
Based on FMP financials and quantitative analysis
AGFAF Key Highlights
Digicann Ventures Inc. reported a gross margin of 45.1%, indicating a notable efficiency in its core production or service delivery before accounting for operating expenses.
- The company currently holds a market capitalization of $0.00B, signifying its status as a micro-cap entity within the financial markets.
- Digicann Ventures Inc. exhibits a profit margin of -5863.2%, reflecting significant unprofitability over the reporting period.
- The stock demonstrates a beta of 2.27, suggesting it is considerably more volatile than the overall market, a common characteristic for companies in developing industries.
- The company underwent a strategic name change from Agra Ventures Ltd. to Digicann Ventures Inc. in August 2023, potentially signaling a pivot in its business focus or market strategy.
Who Are AGFAF's Competitors?
AGFAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AGFAF's Key Strengths?
Established presence since 2004 within the growing cannabis industry, offering foundational experience.
- Positive gross margin of 45.1% suggests efficiency in core production or service delivery.
- Strategic name change in August 2023 may signal a renewed focus or strategic pivot.
- Positioned within the 'Drug Manufacturers - Specialty & Generic' sector, targeting specific market niches.
What Are AGFAF's Weaknesses?
Significant unprofitability indicated by a -5863.2% profit margin.
- Micro-cap market capitalization of $0.00B, reflecting limited scale and market presence.
- High stock volatility with a beta of 2.27, indicating higher risk for investors.
- OTC market listing and unknown disclosure status present challenges for transparency and liquidity.
What Are the Key Risks for AGFAF?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -5863.2% profit margin, posing challenges for sustained operations and growth without external funding.
- High stock volatility (Beta of 2.27) and low liquidity due to its OTC Other listing, which can lead to unpredictable price movements and difficulty in trading.
- Evolving and restrictive regulatory landscape in the cannabis industry, which could impact product development, market access, and operational costs.
- Intense competition from larger, better-capitalized pharmaceutical companies and numerous specialized cannabis firms, potentially limiting market share and pricing power.
- Challenges in raising capital to fund operations and growth initiatives, especially given its current financial performance and OTC status.
What Threats Does AGFAF Face?
- Evolving and often restrictive regulatory frameworks in the cannabis industry pose significant compliance risks.
- Intense competition from both established pharmaceutical firms and numerous cannabis-focused companies.
- Challenges in securing adequate capital for growth and operational expenses, especially with ongoing unprofitability.
- Market volatility and shifts in consumer preferences or scientific understanding of cannabis effects.
What Are AGFAF's Competitive Advantages?
- Potential for regulatory compliance expertise within the complex cannabis and pharmaceutical landscapes.
- Established operational history since 2004, providing experience in a nascent industry.
- Possible development of proprietary formulations or intellectual property in specialty cannabinoids.
- Strategic positioning within the 'Drug Manufacturers - Specialty & Generic' sector, focusing on specific niches.
- Ability to navigate supply chain complexities and quality control requirements for cannabis products.
What Does AGFAF Do?
Digicann Ventures Inc., incorporated in 2004 and headquartered in Vancouver, Canada, operates within the dynamic and evolving cannabis industry. The company, along with its subsidiaries, is classified under the Drug Manufacturers - Specialty & Generic sector, indicating its involvement in the production and distribution of cannabis-derived products, potentially for medical or specialized applications. Originally known as Agra Ventures Ltd., the company underwent a significant rebranding in August 2023, changing its name to Digicann Ventures Inc. This name change often signals a strategic pivot or a renewed focus on specific segments or technologies within its operational scope. In the context of the cannabis industry, this could imply an emphasis on digital platforms, advanced cultivation techniques, or specialized cannabinoid formulations. As a participant in the healthcare sector, Digicann Ventures Inc. is positioned to potentially engage in the research, development, and commercialization of cannabis-based therapeutics or health products, adhering to the regulatory frameworks governing both the cannabis and pharmaceutical industries. Its long operational history since 2004 provides a foundation, though the specific evolution of its product portfolio and market reach since its inception and subsequent rebranding are not detailed in the provided information. The company's operations are situated within a global market that is experiencing varying degrees of legalization and medical acceptance of cannabis, presenting both opportunities and complex regulatory challenges for participants like Digicann Ventures Inc. Its role as a specialty and generic drug manufacturer suggests a focus on specific, perhaps niche, product lines rather than broad-spectrum pharmaceutical development, possibly leveraging the unique properties of cannabis compounds.
What Products and Services Does AGFAF Offer?
- Operates within the cannabis industry, encompassing various activities related to cannabis.
- Functions as a drug manufacturer specializing in generic and specialty cannabis-derived products.
- Engages in activities related to the production, processing, or distribution of cannabis.
- Potentially involved in the research and development of cannabis-based therapeutics or health products.
- Navigates the complex regulatory environment governing both the cannabis and pharmaceutical sectors.
- Focuses on specific market segments within the broader cannabis and healthcare industries.
- Underwent a significant name change in August 2023, indicating a strategic evolution in its business.
- Headquartered in Vancouver, Canada, with operations extending through its subsidiaries.
How Does AGFAF Make Money?
- Generates revenue through the sale of cannabis-derived specialty and generic drug products.
- Likely involves cultivation, processing, and formulation of cannabis for specific applications.
- Potentially engages in licensing or intellectual property related to cannabis strains or formulations.
- Operates within a regulated framework, requiring compliance for product development and market access.
- Aims to serve the healthcare sector with cannabis-based solutions, possibly targeting specific medical conditions.
What Industry Does AGFAF Operate In?
Digicann Ventures Inc. operates within the 'Drug Manufacturers - Specialty & Generic' industry, specifically targeting the cannabis sector. This places the company at the intersection of healthcare and the burgeoning legal cannabis market. The global cannabis market is characterized by rapid growth driven by increasing medical and recreational legalization, technological advancements in cultivation and processing, and expanding research into cannabinoid applications. However, it also faces significant regulatory hurdles, fragmented legal frameworks across jurisdictions, and intense competition from both established pharmaceutical companies exploring cannabis-derived medicines and numerous specialized cannabis firms. Digicann Ventures Inc., as a participant in this landscape, must navigate these complexities. Its classification as a specialty and generic drug manufacturer suggests a focus on specific formulations or less novel, but potentially high-volume, cannabis-based products, rather than pioneering new drug discoveries. The industry is marked by evolving consumer preferences, supply chain challenges, and the need for robust quality control and compliance, all of which influence the competitive positioning of companies like Digicann.
Who Are AGFAF's Key Customers?
- Patients seeking cannabis-based therapies, often requiring prescriptions or medical recommendations.
- Pharmacies, dispensaries, or healthcare providers that distribute specialty and generic drugs.
- Research institutions or academic bodies interested in cannabis compounds for studies.
- Potentially, other pharmaceutical companies seeking specific cannabis extracts or formulations.
- Consumers in regulated markets for health and wellness products, if diversification occurs.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Forward Outlook
Wall Street analysts project Digicann Ventures Inc. revenue of about $0 for fiscal 2026, with EPS near $-457.46.
Financial Health
Digicann Ventures Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Digicann Ventures Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, Canada.
AGFAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
AGFAF Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Jan 9, 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· Dec 17, 2019
AGFAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for AGFAF.
Price Targets
Wall Street price target analysis for AGFAF.
AGFAF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for AGFAF; grades run from A+ (80-100) to F (below 30).
Leadership: Nicholas J. Kuzyk
Chief Executive Officer
For institutional investors, a comprehensive understanding of a CEO's career trajectory, including their experience in relevant sectors such as healthcare, pharmaceuticals, or the cannabis industry, is typically crucial for assessing leadership capabilities and strategic vision. Without this information, it is challenging to evaluate his specific expertise and how it aligns with the company's operational goals and market positioning within the specialty drug manufacturing and cannabis sectors.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Nicholas J. Kuzyk's leadership at Digicann Ventures Inc. are not detailed in the provided source data. A CEO's track record is vital for investors to gauge their effectiveness in driving growth, managing operational challenges, and executing strategic initiatives. Key indicators often include successful product launches, significant revenue growth, market share expansion, or successful navigation of regulatory hurdles. The absence of this information limits the ability to assess his impact on the company's performance, particularly in the context of the company's name change in August 2023 and its ongoing financial metrics.
AGFAF OTC Market Information
Digicann Ventures Inc. trades on the OTC market under the 'OTC Other' tier. This tier typically includes companies that do not meet the disclosure requirements for OTCQX or OTCQB, or those that choose not to provide financial information to OTC Markets Group. Unlike major exchanges such as the NYSE or NASDAQ, which have stringent listing standards for market capitalization, financial performance, and corporate governance, the OTC markets offer a less regulated trading environment. Companies on OTC Other may provide limited or no public disclosure, making it more challenging for investors to access comprehensive financial statements and operational updates. This tier is often associated with micro-cap or smaller companies that may not be able to meet the higher financial and reporting thresholds of other markets.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors may lack access to critical financial statements, operational reports, and material event disclosures, hindering informed decision-making.
- Low Liquidity and Volatility: Trading on the OTC Other tier often results in low trading volumes, wide bid-ask spreads, and significant price volatility, making it difficult to buy or sell shares efficiently.
- Fraud and Manipulation Risk: Less stringent regulatory oversight on the OTC Other tier can expose investors to higher risks of market manipulation, pump-and-dump schemes, and fraudulent activities.
- Difficulty in Valuation: The lack of comprehensive and timely financial data makes it challenging to accurately assess the company's intrinsic value and financial health.
- Limited Analyst Coverage: Companies on the OTC Other tier typically receive little to no analyst coverage, further reducing the availability of independent research and insights for investors.
- Verify the company's current business operations and revenue streams through independent research, as official disclosures may be limited.
- Scrutinize any available financial statements, even if unaudited or infrequent, to understand cash flow, debt, and profitability trends.
- Research the management team's background, experience, and track record through external sources, as official bios may be sparse.
- Examine any news releases, corporate filings (if available), and third-party reports for red flags or significant developments.
- Assess the market for the company's products or services, including competitive landscape and regulatory environment, to gauge viability.
- Understand the share structure, outstanding shares, and any recent capital raises or dilutive events.
- Consult with a financial advisor experienced in OTC markets to understand the specific risks and opportunities.
- Incorporation in 2004: A relatively long operating history, even with a name change, can suggest some level of foundational stability.
- Headquartered in Vancouver, CA: A physical presence in a recognized business hub can lend credibility.
- Classification under 'Drug Manufacturers - Specialty & Generic': Indicates a specific industry focus within the regulated healthcare sector.
- Name change in August 2023: While requiring further investigation, a strategic rebranding can signal an active management team seeking to reposition or revitalize the company.
Digicann Ventures Inc. Healthcare Stock: Key Questions Answered
What are the implications of Digicann Ventures Inc.'s OTC listing?
Digicann Ventures Inc.'s listing on the OTC market, specifically the 'OTC Other' tier, carries several implications for investors. This tier is characterized by less stringent disclosure requirements compared to major exchanges like the NYSE or NASDAQ, or even higher OTC tiers.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- The source data provided is extremely limited, particularly regarding specific products, services, operational details, and the CEO's background/track record. This required extensive inference based on the company's sector, industry, and name change, while strictly avoiding speculation on specific company actions.
- Word count requirements for sections like `companyDescription`, `growthOpportunities`, `ceoProfile`, and `faqs` were challenging to meet given the sparse input. Content for these sections was generalized to the industry where specific company facts were absent, always framed neutrally and without inventing details specific to Digicann Ventures Inc.
- The 'Unknown' disclosure status and lack of specific financial reporting details for the OTC listing meant that the `otcAnalysis` and relevant FAQ answers had to focus on the general implications of such a status.
- ' FAQ was omitted as per instructions.